Article

Targeting the translational machinery in gastrointestinal stromal tumors (GIST) – a new therapeutic vulnerability

2021-09-03

Abstract excerpt

<h4>ABSTRACT</h4> Although KIT -mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the KIT receptor tyrosine kinase gene indicating continued dependency on the KIT signaling pathway...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 052ba5b1-b44c-55a6-a754-d109bc6e0eb2
DOI: 10.1101/2021.09.01.458633

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting the translational machinery in gastrointestinal stromal tumors (GIST) – a new therapeutic vulnerabilityDOI 10.1101/2021.09.01.458633Read

Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.Semantic proximity Read

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update.Semantic proximity Read

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.Semantic proximity Read

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read

Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors.Semantic proximity Read

Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Semantic proximity Read

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.Semantic proximity Read

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor.Semantic proximity Read

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read

KIT mutations in GIST.Semantic proximity Read